The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study.

Authors:
McDermott G; Fu X; Cook C; Ahola C; Doliner B and 5 more

Journal:
Ann Rheum Dis

Publication Year: 2022

DOI:
10.1136/annrheumdis-2022-222439

PMCID:
PMC9474699

PMID:
35697489

Journal Information

Full Title: Ann Rheum Dis

Abbreviation: Ann Rheum Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests: ZSW has performed consultancy for Viela Bio/Horizon, MedPace, Zenas Biopharma, and Sanofi/Principia. ZSW has received grant support from BMS and Sanofi/Principia for unrelated work."

Evidence found in paper:

"Funding: GCM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR055855). ZSW is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR073334 and R03AR078938), the Rheumatology Research Foundation (K Supplement), and a COVID-19 Junior Investigator Award from the Massachusetts General Hospital Department of Medicine. Competing interests:ZSW has performed consultancy for Viela Bio/Horizon, MedPace, Zenas Biopharma, and Sanofi/Principia. ZSW has received grant support from BMS and Sanofi/Principia for unrelated work."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025